Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:JANX NASDAQ:NUVL NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$56.09-0.3%$49.63$30.04▼$71.13$4.86B1.83.67 million shs2.99 million shsJANXJanux Therapeutics$23.56-1.9%$24.74$22.48▼$71.71$1.42B2.86800,036 shs601,583 shsNUVLNuvalent$77.76-0.8%$78.69$55.53▼$113.51$5.63B1.3463,959 shs376,599 shsTGTXTG Therapeutics$35.02-1.4%$36.83$16.65▼$46.48$5.64B1.951.51 million shs2.32 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-0.30%-13.39%+8.55%+46.64%-2.09%JANXJanux Therapeutics-1.87%-9.24%-2.08%-28.35%-41.97%NUVLNuvalent-0.75%-4.48%-3.40%+0.39%-2.73%TGTXTG Therapeutics-1.35%-5.09%-3.50%-19.38%+77.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.5139 of 5 stars4.32.00.00.03.03.30.6JANXJanux Therapeutics2.7535 of 5 stars3.52.00.00.04.12.50.0NUVLNuvalent3.1791 of 5 stars4.51.00.00.02.83.30.0TGTXTG Therapeutics4.0717 of 5 stars3.40.00.03.52.92.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.50Moderate Buy$70.0724.92% UpsideJANXJanux Therapeutics 3.08Buy$91.89290.02% UpsideNUVLNuvalent 3.09Buy$119.6053.81% UpsideTGTXTG Therapeutics 2.80Moderate Buy$43.8025.07% UpsideCurrent Analyst Ratings BreakdownLatest JANX, TGTX, NUVL, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025CRSPCRISPR TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$79.00 ➝ $78.007/21/2025NUVLNuvalentWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$115.007/11/2025JANXJanux TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.007/10/2025TGTXTG TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$37.007/8/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/30/2025NUVLNuvalentThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/27/2025CRSPCRISPR TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.006/27/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.006/27/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.006/26/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$37.31M129.83N/AN/A$22.64 per share2.48JANXJanux Therapeutics$9.34M149.33N/AN/A$19.49 per share1.21NUVLNuvalentN/AN/AN/AN/A$14.99 per shareN/ATGTXTG Therapeutics$329M16.90$0.12 per share295.93$1.43 per share24.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)NUVLNuvalent-$260.76M-$4.39N/AN/AN/AN/A-31.35%-29.27%8/14/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.24145.9235.02N/A10.13%18.88%7.05%8/4/2025 (Estimated)Latest JANX, TGTX, NUVL, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025NUVLNuvalent-$1.27N/AN/AN/AN/AN/A8/6/2025Q2 2025JANXJanux Therapeutics-$0.50N/AN/AN/A$0.30 millionN/A8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.54N/AN/AN/A$6.44 millionN/A8/4/2025Q2 2025TGTXTG Therapeutics$0.27N/AN/AN/A$147.76 millionN/A5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 million5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A15.6415.64JANXJanux TherapeuticsN/A58.4758.47NUVLNuvalentN/A14.4814.48TGTXTG Therapeutics1.034.023.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%JANXJanux Therapeutics75.39%NUVLNuvalent97.26%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%JANXJanux Therapeutics8.10%NUVLNuvalent10.20%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46086.36 million82.65 millionOptionableJANXJanux Therapeutics3059.18 million54.38 millionOptionableNUVLNuvalent4071.81 million64.48 millionOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableJANX, TGTX, NUVL, and CRSP HeadlinesRecent News About These CompaniesTG Therapeutics (TGTX) to Release Quarterly Earnings on Monday2 hours ago | americanbankingnews.com12,618 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Baader Bank AktiengesellschaftAugust 1 at 6:03 AM | marketbeat.comThe Play On TG TherapeuticsJuly 30 at 12:22 AM | seekingalpha.comTG Therapeutics (TGTX) to Release Quarterly Earnings on TuesdayJuly 30 at 8:18 AM | marketbeat.comTG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business UpdateJuly 30 at 7:30 AM | globenewswire.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Meeder Asset Management Inc.July 30 at 5:48 AM | marketbeat.comTG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 ReleaseJuly 29, 2025 | zacks.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Victory Capital Management Inc.July 28, 2025 | marketbeat.comNeo Ivy Capital Management Buys New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)July 27, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Buys Shares of 199,050 TG Therapeutics, Inc. (NASDAQ:TGTX)July 27, 2025 | marketbeat.comY Intercept Hong Kong Ltd Purchases New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)July 27, 2025 | marketbeat.comTeachers Retirement System of The State of Kentucky Grows Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)July 23, 2025 | marketbeat.comIFP Advisors Inc Has $7.42 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)July 20, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Hussman Strategic Advisors Inc.July 18, 2025 | marketbeat.comJackson Creek Investment Advisors LLC Has $1.40 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)July 18, 2025 | marketbeat.comEdgestream Partners L.P. Increases Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 18, 2025 | marketbeat.comSigma Planning Corp Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 17, 2025 | marketbeat.comBank of New York Mellon Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 15, 2025 | marketbeat.comTG Therapeutics (TGTX) Gets a Hold from Goldman SachsJuly 12, 2025 | theglobeandmail.comBanque Pictet & Cie SA Acquires Shares of 13,151 TG Therapeutics, Inc. (NASDAQ:TGTX)July 11, 2025 | marketbeat.comTG Therapeutics Joins Rank Of Stocks With RS Ratings Over 90July 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJANX, TGTX, NUVL, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$56.09 -0.17 (-0.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$56.14 +0.05 (+0.09%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Janux Therapeutics NASDAQ:JANX$23.56 -0.45 (-1.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$23.59 +0.03 (+0.13%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Nuvalent NASDAQ:NUVL$77.76 -0.59 (-0.75%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$77.76 -0.01 (-0.01%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.TG Therapeutics NASDAQ:TGTX$35.02 -0.48 (-1.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$35.33 +0.31 (+0.87%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
